The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions

Expert Opinion on Drug Discovery

Volumn 3, Issue 9, 2008, Pages 1027-1040

  Decker, Michael W ^a   Gopalakrishnan, Murali ^a   Meyer, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Alzheimer's disease; Analgesia; Attention deficit hyperactivity disorder; Cognitive deficits of schizophrenia; Nicotinic acetylcholine receptors; Pain; Parkinson's disease; Smoking cessation

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; A 366833; A 582941; AMFEBUTAMONE; AR R 1779; AZD 3480; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIANICLINE; EPIBATIDINE; ISPRONICLINE; MEM 3454; NICOTINE; NICOTINIC AGENT; NS 1738; PHA 543613; PLACEBO; PNU 120596; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; SSR 180711A; TC 2696; TC 5619; TC 6499; UNCLASSIFIED DRUG; VARENICLINE;

ADRENERGIC TRANSMISSION; AGITATION; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ATTENTION DEFICIT DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; DIZZINESS; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG LABELING; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MEMORY DISORDER; MOLECULAR BIOLOGY; MOOD DISORDER; MOTOR PERFORMANCE; NAUSEA; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PAIN; PARKINSON DISEASE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SMOKING CESSATION; SUICIDAL IDEATION; TOBACCO DEPENDENCE; UNPLEASANT DREAM; VIVID DREAM; VOMITING;

EID: 52649163503     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.9.1027     Document Type: Review

References (120)

1. Arneric SP, Holladay M, Williams M. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol 2007;74:1092-101
2. Lukas RJ, Changeux JP, Le Novere N, et al. International union of pharmacology. XX Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev 1999;51:397-401
3. Gotti C, Moretti M, Gaimarri A, et al. Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 2007;74:1102-11
4. Tapia L, Kuryatov A, Lindstrom J. Ca2+ permeability of the (alpha4)3(beta2)2 stoichiometry greatly exceeds that of (alpha4)2(beta2)3 human acetylcholine receptors. Mol Pharmacol 2007;71:769-76
5. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002;3:102-14
6. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Ann Rev Pharmacol Toxicol 2007;47:699-29
7. Picciotto MR, Caldarone BJ, King SL, et al. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 2000;22:451-65
8. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: Behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 2006;184:523-39
9. Lightfoot AP, Kew JNC, Skidmore J. α7 nicotinic acetylcholine receptor agonists and positive allosteric modulators. Progress Med Chem 2008;46:131-71
10. Bitner RS, Bunnelle WH, Anderson DJ, et al. Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of erk 1/2 and creb phosphorylation pathways. J Neurosci 2007;27:10578-87
11. Kem WR. The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of alzheimer's disease: Studies with DMXBA (GTS-21). Behav Brain Res 2000;113:169-81
12. Curzon P, Anderson DJ, Nikkel AL, et al. Antisense knockdown of the rat α7 nicotinic acetylcholine receptor produces spatial memory impairment. Neurosci Lett 2006;410:15-9
13. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 2005;4:673-84
14. Grady SR, Salminen O, Laverty DC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 2007;74:1235-46
15. Vetter DE, Katz E, Maison SF, et al. The alpha10 nicotinic acetylcholine receptor subunit is required for normal synaptic function and integrity of the olivocochlear system. Proc Natl Acad Sci USA 2007;104:20594-9
16. De Biasi M. Nicotinic mechanisms in the autonomic control of organ systems. J Neurobiol 2002;53:568-79
17. Nelson ME, Wang F, Kuryatov A, et al. Functional properties of human nicotinic achrs expressed by IMR-32 neuroblastoma cells resemble those of α3β4 AChRs expressed in permanently transfected HEK cells. J Gen Physiol 2001;118:563-82
18. Johnson E. AZD3480, a selective neuronal nicotinic receptor agonist with properties for treating cognition dysfunction. Wellcome Trust Conference; 2008; Hinxton, UK
19. Kuryatov A, Onksen J, Lindstrom JM. Roles of accessory subunits in α4β2* nicotinic receptors. Mol Pharmacol 2008;74:132-43
20. Newhouse PA, Potter A, Kelton M, et al. Nicotinic treatment of Alzheimer's disease. Biol Psychiatry 2001;49:268-78
21. Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 2004;4:36-46
22. Quik M, Bordia T, O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem Pharmacol 2007;74:1224-34
23. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997;20:92-8
24. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-8
25. Perry E, Martin-Ruiz C, Lee M, et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000;393:215-22
26. Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology. Neuroscience 1995;64:385-95
27. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications. Biol Psychiatry 2001;49:200-10
28. Bencherif M, Bane AJ, Miller CH, et al. TC-2559: A novel orally active ligand selective at neuronal acetylcholine receptors. Eur J Pharmacol 2000;409:45-55
29. Rueter LE, Anderson DJ, Briggs CA, et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev 2004;10:167-82
30. Wesnes K, Revell A. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 1984;84:5-11
31. Quik M, Cox H, Parameswaran N, et al. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62:588-96
32. Villafane G, Cesaro P. Rialland A, et al. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol 2007;14:1313-6
33. Potter A, Corwin J, Lang J, et al. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease.Psychopharmacology (Berl) 1999;142:334-42
34. Owen RT, Serradell N, Rosa E. Ispronicline. Nicotinic acetylcholine α4β2 agonist, treatment of cognition disorders. Drugs Future 2008;33:197-202
35. Dunbar GC, Inglis F, Kuchibhatla R, et al. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 2007;21:171-8
36. Memory Pharmaceuticals announces positive phase 2a results for MEM 3454 in Alzheimer's disease, Memory Pharmaceuticals Corp., Montvale, NJ, 2007. Available from: http://phx.corporate-ir.net/ phoenix.zhtml?c=175500&p=irol-ewsArticle&t= Regular&id=1071665& [Last accessed 7 May 2008]
37. Buccafusco JJ, Terry AV, Decker MW, et al. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol 2007;74:1202-11
38. The Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 2006;66:408-10
39. O'Leary K, Parameswaran N, McIntosh JM, et al. Cotinine selectively activates a subpopulation of α3/α6β2 nicotinic receptors in monkey striatum. J Pharmacol Exp Ther 2008;325:646-54
40. Quik M, McIntosh JM. Striatal α6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. J Pharmacol Exp Ther 2006;316:481-9
41. Park HJ, Lee PH, Ahn YW, et al. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci 2007;26:79-89
42. Court J, Keverne J, Svedberg M, et al. Nicotine reduces Aβ in the brain and cerebral vessels of APPsw mice. Eur J Neurosci 2004;19:2703-10
43. Liu Q, Zhang J, Zhu H, et al. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J 2007;21:61-73
44. Shimohama S, Kihara T. Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. Biol Psychiatry 2001;49:233-9
45. Wang HY, Lee DH, Davis CB, et al. Amyloid peptide Aβ(1-42) binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors. J Neurochem 2000;75:1155-61
46. Spencer JP, Weil A, Hill K, et al. Transgenic mice over-expressing human β-amyloid have functional nicotinic α7 receptors. Neuroscience 2005;137:795-805
47. Oddo S, Caccamo A, Green KN, et al. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci USA 2005;102:3046-51
48. Carson R, Craig D, McGuinness B, et al. α7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer's disease. J Med Genet 2008;45:244-8
49. Sarter M, Hasselmo ME, Bruno JP, et al. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Rev 2005;48:98-111
50. Hahn B, Sharples CGV, Wonnacott S, et al. Attentional effects of nicotinic agonists in rats. Neuropharmacology 2003;44:1054-67
51. Rowe DL, Hermens DF. Attention-deficit/hyperactivity disorder: neurophysiology, information processing, arousal and drug development. Exp Rev Neurother 2006;6:1721-34
52. Grottick AJ, Higgins GA. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res 2000;117:197-208
53. Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol 2007;74:1212-23
54. Wilens T, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/ hyperactivity disorder in adults: Results of a pilot study. Biol Psychiatry 2006;59:1065-70
55. Wilens TE, Biederman J, Spencer TJ, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 1999;156:1931-7
56. Sullivan JP, Donnelly-Roberts D, Briggs CA, et al. ABT-089 [2-methyl-3(2-(s)-pyrrolidinylmethoxy) pyridine]. 1. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 1997;283:235-46
57. Parikh V, Man K, Decker MW, et al. Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholincrgic transients in the prefrontal cortex. J Neurosci 2008;28:3769-80
58. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007;33:1100-19
59. Geyer MA, Heinssen R. New approaches to measurement and treatment research to improve cognition in schizophrenia. Schizophr Bull 2005;31:806-9
60. Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33:1120-30
61. Stevens KE, Freedman R, Collins AC, et al. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and α-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 1996;15:152-62
62. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63:630-38
63. Radek RJ, Miner HM, Bratcher NA, et al. α4β2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating. Psychopharmacology 2006;187:47-55
64. Davis L, Pollock LJ, Stone T. Visceral pain. Surg Gynecol Obstet 1932;55:418-26
65. Daly JW, Garraffo HM, Spande TF, et al. Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics. Nat Prod Rep 2000;17:131-5
66. Decker MW, Rueter LE, Bitner RS. Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr Top Med Chem 2004;4:369-84
67. Decker MW, Meyer MD, Sullivan JP. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs 2001;10:1819-30
68. Rueter LE, Kohlhaas KL, Curzon P, et al. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain 2003;103:269-76
69. Vincler M. Neuronal nicotinic receptors as targets for novel analgesics. Expert Opin Investig Drugs 2005;14:1191-8
70. Damaj MI, Fonck C, Marks MJ, et al. Genetic approaches identify differential roles for α4β2* nicotinic receptors in acute models of antinociception in mice. J Pharmacol Exp Ther 2007; 321:1161-9
71. Vincler M, Wittenauer S, Parker R, et al. Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors. Proc Natl Acad Sci USA 2006;103:17880-4
72. Meyer MD, Anderson DJ, Campbell JE, et al. Preclinical pharmacology of ABT-594: a nicotinic acetylcholine receptor agonist for the treatment of pain. CNS Drug Rev 2000;6:183-93
73. Targacept announces results of phase II study of TC-2696 in postoperative dental pain, Targacept, Inc., Winston-Salem, NC, 2007. Available from: http://www.targacept.com/wt/page/pr_1196665010 [Last accessed 7 May 2008]
74. GSK pulls backing from failed Targacept drug candidate, WRAL.com, 2007. Available from: http://www.wral.com/business/local_tech_wire/biotech/ story/2202123/ [Last accessed 7 May 2008]
75. Targacept to receive $6 million from GlaxoSmithKline for initiation of phase I trial of neuropathic pain candidate, Targacept, Inc., Winston-Salem, NC, 2007. Available from: http://www.targacept.com/ wt/page/pr_1197055543 [Last accessed 7 May 2008]
76. Meyer MD. Preclinical and clinical studies with novel nAChR ligands in pain. presentation at Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research and Clinical Science (Soc Neurosci Satellite Symposium); 2007; San Diego, CA
77. Rose JE, Levin ED. Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. Pharmacol Biochem Behav 1992;41:219-26
78. Rollema H, Coe JW, Chambers LK, et al. Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007;28:316-25
79. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52:985-94
80. Cohen C, Bergis OE, Galli F, et al. SSR591813, a novel selective and partial α4β2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003;306:407-20
81. 2007 earnings ahead of guidance - sharp rise in proposed dividend, Aanofi-Aventis, Paris, 2008. Available from: http://en.sanofi-aventis.com/press/ppc_20303.asp#3 [Last accessed 9 May 2008]
82. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-56
83. Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation. Am J Med 2008;121:S32-42
84. Rose JE. Multiple brain pathways and receptors underlying tobacco addiction. Biochem Pharmacol 2007;74:1263-70
85. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006;63:907-14
86. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at ↓ neuronal nicotinic receptors. Mol Pharmacol 2006;70:801-5
87. Mao D, Yasuda RP. Fan H, et al. Heterogeneity of nicotinic cholinergic receptors in rat superior cervical and nodose ganglia. Mol Pharmacol 2006;70:1693-9
88. Wang N, Orr-Urtreger A, Korczyn AD. The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Prog Neurobiol 2002;68:341-60
89. Wang N, Orr-Urtreger A, Chapman J, et al. Deficiency of nicotinic acetylcholine receptor β4 subunit causes autonomic cardiac and intestinal dysfunction. Mol Pharmacol 2003;63:574-80
90. Wang N, Orr-Urtreger A, Chapman J, et al. Autonomic function in mice lacking α5 neuronal nicotinic acetylcholine receptor subunit. J Physiol 2002;542:347-54
91. Franceschini D, Orr-Urtreger A, Yu W, et al. Altered baroreflex responses in α7 deficient mice. Behav Brain Res 2000;113:3-10
92. Deck J, Bibevski S, Gnecchi-Ruscone T, et al. α7-nicotinic acetylcholine receptor subunit is not required for parasympathetic control of the heart in the mouse. Physiol Genomics 2005;22:86-92
93. Xu W, Orr-Urtreger A, Nigro F, et al. Multiorgan autonomic dysfunction in mice lacking the β2 and the β4 subunits of neuronal nicotinic acetylcholine receptors. J Neurosci 1999;19:9298-305
94. Ji J, Bunnelle WH, Anderson DJ, et al. A-366833: A novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane α4β2 nicotinic acetylcholine receptor selective agonist: synthesis, analgesic efficacy and tolerability profile in animal models. Biochem Pharmacol 2007;74:1253-1262
95. Rose JE, Corrigall WA. Nicotine self-administration in animals and humans: Similarities and differences. Psychopharmacology 1997;130:28-40
96. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of α4* receptors: Sufficient for reward, tolerance, and sensitization. Science 2004;306:1029-32
97. Epping-Jordan MP, Watkins SS, Koob GF, et al. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998;393:76-9
98. Varenicline (marketed as Chantix) information, US Food and Drug Administration, Rockville, MD. 2008.Available from: http://www.fda.gov/ cder/drug/infopage/varenicline/default.htm [Last accessed 16 June 2008]
99. 3H]A-585539 [(1s,4s)-2,2-dimethyl-5- (6-phenylpyridazin-3-yl)- 5-aza-2-azoniabicyclo [2.2.1]heptane], a novel high-affinity α7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain. J Pharmacol Exp Ther 2008;324:179-87
100. 3H]methylcarbamylcholine in rat brain. Eur J Pharmacol 1994; 253:261-7
101. 3H]methyllycaconitine: a new radioligand for labelling α7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 1999;38:679-90
102. 3H] epibatidine binding to cholinergic receptors in rat and human brain. Mol Pharmacol 1995;48:280-7
103. Salminen O, Whiteaker P, Grady SR, et al. The subunit composition and pharmacology of α-conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay. Neuropharmacology 2005;48:696-705
104. 125I]-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. Mol Pharmacol 2000; 57:913-25
105. Dunlop J, Bowlby M, Peri R, et al. High throughput electrophysiology: an emerging paradigm for ion channel screening and physiology. Nat Rev Drug Discov 2008;7:358-68
106. Grady SR, Salminen O, Laverty DC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 2007;74:1235-46
107. 3H]-norepinephrine from rat brain slices using a new 96-well format assay. Neuropharmacology 2000;39:2663-72
108. Bunnelle WH, Decker MW. Neuronal nicotinic acetylcholine receptor ligands as potential analgesics. Expert Opin Ther Patent 2003;13:1003-21
109. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7
110. Cosford ND, Bleicher L, Vernier JM, et al. Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist. Pharm Acta Helvetiae 2000;74:125-30
111. Bisson WH, Scapozza L, Westera G, et al. Ligand selectivity for the acetylcholine binding site of the rat α4β2 and α3β4 nicotinic subtypes investigated by molecular docking. J Med Chem 2005;48:5123-30
112. Sullivan JP, Donnelly-Roberts D, Briggs CA, et al. A-85380 [3-(2(s)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand. Neuropharmacology 1996;35:725-34
113. Menzaghi F, Whelan KT, Risbrough VB, et al. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J Pharmacol Exp Ther 1997;280:384-92
114. Schneider JS, Pope-Coleman A, Van Velson M, et al. SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov Disord 1998;13:637-42
115. Geerts H. Ispronicline (Targacept). Curr Opin Investig Drugs 2006;7:60-9
116. Lightfoot AP, Ken JNC, Skidmore J. α7 nicotinic acetylcholine receptor agonists and positive allosteric modulators. Prog Med Chem 2008; 46:131-71
117. Wang S, Dragan S, Sun S, et al. MEM-3454, a novel nicotinic α7 receptor partial agonist I. In vitro pharmacological profiling. Soc Neurosci Abstract 2006:163.2
118. Bertrand D, Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 2007;74:1155-63
119. Gronlein J-H, Håkerud M, Ween H, et al. Distinct profiles of α7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 2007;72:715-24
120. Faghih R, Gopalakrishnan M, Briggs CA. Allosteric modulators of the α7 nicotinic acetylcholine receptor. J Med Chem 2008;51:701-12